Endocrinology and Metabolism10.3803/enm.2021.10072021362312-321Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint InhibitorsShintaro Iwama, Tomoko Kobayashi, Hiroshi Arima,,
Cancer10.1002/cncr.31200201812461111-1121Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical managementRomualdo Barroso-Sousa, Patrick A. Ott, F. Stephen Hodi, Ursula B. Kaiser, Sara M. Tolaney, Le Min,
Endocrine Emergencies10.1016/b978-0-323-76097-3.00024-72022301-314Endocrinopathies Associated With Immune Checkpoint InhibitorsMonica Girotra,
Cancer Cytopathology10.1002/cncy.219512017126111-19Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathologyDouglas P. Clark,
Immune Network10.4110/in.2020.20.e92020201Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint InhibitorsJuwhan Choi, Sung Yong Lee,,
Annals of Oncology10.1016/j.annonc.2021.05.440202132S255SY10-4 Clinical biomarkers to predict the efficacy of immune checkpoint inhibitorsSatoru Miura,
Clinical and Translational Oncology10.1007/s12094-021-02579-920212391782-1793Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)J. Liu, Q. Wu, S. Wu, X. Xie,,
Clinical Neurophysiology10.1016/j.clinph.2018.02.05420181295e27-e28S12-4. Myasthenia gravis induced by immune checkpoint inhibitorsShigeaki Suzuki,
Clinical Endocrinology10.1111/cen.130632016853331-339Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical reviewM.N Joshi, B.C. Whitelaw, M.T.P. Palomar, Y. Wu, P.V. Carroll
ESMO Open10.1136/esmoopen-2020-000791202054e000791Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancerByung Woog Kang, Ian Chau,,